News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
News UK aims to cut four years from drug development process NICE, regulator and NHS should work together, according to review.
News Can Keytruda beat Opdivo to full UK access in lung cancer? A decisive moment in lung cancer treatment is nearing
News NICE proposals could cut wait for specialist treatments and ... Technologies for very rare conditions will also be automatically funded.
Views & Analysis NICE and NHS England unveil ‘fast-track’ and affordability s... NHS England will be able to control cost impact of NICE decisions more directly.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
